Gunda Georg inducted into Medicinal Chemistry Hall of Fame
Dr. Gunda Georg, professor and head of the Department of Medicinal Chemistry, was inducted this year into the ACS Medicinal Chemistry Hall of Fame during the American Chemical Society meeting which took place on August 22nd in Washington D.C. This highly-selective award, granted to less than 100 individuals since its creation in 1966, recognizes Dr. Georg as a senior scientist whose long-standing research and teaching contributions have had significant impacts in the field of Medicinal Chemistry. Read more about her career and contributions here and about the ACS Medicinal Chemistry Hall of Fame here.Previous inductees from the University of Minnesota Department of Medicinal Chemistry include Phillip Portoghese and Robert Vince.
A new drug for pancreatic cancer takes the stage for clinical trials
What does it take to get to that moment in a clinic when a doctor gives a patient a compound never before used in modern medicine? The story of Minnelide, an investigational drug for pancreatic cancer patients now in a Phase IA clinical trial at the University of Minnesota, illustrates just how complex and exhilarating that journey can be.
Gunda Georg Inducted into the Academy for Excellence in Health Research
The Academy for Excellence in Health Research is the highest recognition of excellence in research by Academic Health Center faculty
Welcome to the Institute for Therapeutics Discovery & Development
ITDD creates opportunities for drug discovery and early pre-clinical drug development through collaborations between various schools, colleges and research centers, as well as industrial throughout Minnesota and nationwide.
Hormone-Free Birth Control Research Advances
Researchers will investigate pharmaceutical alternatives to existing hormone-based birth control under a new $8.3M NIH contract.
The Journal of Medicinal Chemistry
The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.
"Next Generation Inhibitors: From Design to Clinical Development"
October 6, 2017
Dr. Mark Hixon
Director, Institute for Therapeutics Discovery and Development
Professor and Department Head, Department of Medicinal Chemistry; Robert Vince Endowed Chair; McKnight Presidential Chair
Dr. Georg’s expertise includes synthetic medicinal agents, natural products chemistry, and the development of new synthetic methods. She is the co-inventor of Lusedra® and several other drug candidates, as well as the co-founder of ProQuest Pharmaceuticals, Inc. (now a part of Eisai Pharmaceuticals). The ITDD core directors have extensive academic and industrial drug discovery and development expertise. The group uses advanced research and development techniques, including high through-put screening, structure-based drug design, computer modeling, chem- and bioinformatics methods, and animal models to translate basic biomedical discoveries towards new approaches for prevention, treatment, and cures